The first half of 2025 has delivered a sequence of large-cap transactions that signal a decisive shift in corporate confidence. From KKR’s acquisition of EDF’s North American renewables unit to Merck KGaA’s $11.3 billion move on Bio-Techne, the deal landscape is no longer recovering — it is expanding. With Morgan Stanley projecting global M&A activity to reach a record $6.4 trillion in 2026, boards and executive teams must treat strategic transactions not as opportunistic responses but as core instruments of long-term value creation.

Cross-Border Consolidation: Europe and the U.S. Converge on Technology, Life Sciences, and Energy

The current wave of cross-border deals is defined by a clear directional logic: European strategic acquirers are targeting U.S. assets with deep technology or proprietary data moats, while U.S. private equity continues to extract value from European infrastructure and energy carve-outs.

Merck KGaA’s agreement to acquire Bio-Techne for $11.3 billion is one of the most consequential life-sciences transactions in recent years. It reflects a broader imperative among European pharma and diagnostics groups to accelerate their presence in the U.S. biologics and proteomics market — a segment where organic growth timelines are structurally too slow relative to competitive pressure. For General Counsel and M&A Directors managing cross-border mandates, this deal underscores the importance of early-stage due diligence on U.S. regulatory exposure, including FDA compliance posture and existing licensing arrangements.

In parallel, ON Semiconductor’s all-stock acquisition of Synaptics — valued at approximately $7 billion — illustrates how semiconductor and AI-enabled device manufacturers are using mergers and acquisitions to close capability gaps that organic R&D cannot bridge within acceptable timeframes. The all-stock structure is itself a signal: in a higher-rate environment, equity-funded deals preserve balance sheet flexibility while allowing acquirers to share upside with target shareholders.

Private Equity Carve-Outs: Infrastructure Assets Remain a Structural Priority

KKR’s agreement to acquire EDF Power Solutions — EDF’s U.S. and Canada renewables business — is emblematic of a broader private equity thesis: regulated or quasi-regulated infrastructure assets with long-dated contracted cash flows offer defensible returns in a volatile macro environment. For large-cap buyout firms, energy transition assets represent a convergence of ESG mandate compliance, inflation-linked revenue, and government policy tailwinds across both the EU and North America.

For CFOs evaluating carve-out readiness, the EDF transaction offers a useful reference point. Successful infrastructure carve-outs require clean separation of shared services, clearly ring-fenced regulatory licences, and a post-merger integration blueprint that accounts for workforce transition obligations under both U.S. and Canadian labour frameworks. Failure to address these structural complexities in the pre-signing phase routinely leads to value erosion in the 12 to 24 months following close.

Safran’s move into exclusive negotiations to acquire Exail Technologies further reinforces consolidation dynamics in European defence and dual-use technology — a sector where regulatory pre-clearance under foreign investment screening regimes (including France’s décret Montebourg and the EU’s FDI Screening Regulation) is increasingly non-trivial and must be modelled into deal timelines from day one.

Regulatory and Antitrust Complexity: A Material Execution Variable

Across all three thematic vectors — technology, life sciences, and energy — regulatory scrutiny has become a first-order deal execution variable rather than a closing condition to be managed late in the process. Competition authorities in the EU, U.S., and UK are applying heightened review standards to transactions involving data concentration, critical infrastructure, and healthcare market consolidation.

For deal teams, this translates into concrete preparation requirements:

  • Early engagement with antitrust counsel in all relevant jurisdictions, particularly where the combined entity exceeds market share thresholds in regulated sectors
  • Robust corporate finance modelling that stress-tests deal economics against extended regulatory timelines or conditional approval scenarios
  • Board-level awareness that remedies — including behavioural commitments or structural divestitures — may be required to obtain clearance in sensitive sectors

Implications for Decision-Makers: Preparing for a Record Deal Environment

The convergence of elevated deal volumes, cross-border complexity, and regulatory friction creates both opportunity and execution risk for acquirers and targets alike. Organisations that invest now in strengthening their M&A infrastructure — governance frameworks, integration playbooks, regulatory mapping, and venture capital pipeline visibility — will be structurally better positioned to capture value as the cycle accelerates toward 2026.

Key takeaway: The $6.4 trillion M&A outlook is not a forecast to observe passively. For CFOs, General Counsel, and board members, it is a planning horizon that demands proactive portfolio review, counterparty readiness assessments, and a clear-eyed view of where regulatory exposure could constrain deal execution in the sectors and geographies that matter most to your organisation.